 MELBOURNE, Australia, Jan. 5, 2022 PRNewswire -- Alterity Therapeutics ASX: ATH, NASDAQ: ATHE Alterity or the Company, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present at the H.C. 